-+ 0.00%
-+ 0.00%
-+ 0.00%

Hong Kong became a member of the supervisory authority of the “International Human Drug Registration Technical Coordination Council”, a key step in building an international healthcare innovation hub

Zhitongcaijing·11/20/2026 07:41:13
Listen to the news

The Zhitong Finance App learned that on November 20, the Hong Kong Medical and Health Council announced that Hong Kong, China has officially joined the “International Human Drug Registration Technical Coordination Committee” (ICH) as a member of the supervisory authority. ICH is an important international coordination platform for drug regulatory technical standards. Hong Kong officially became an ICH member, representing that the level of drug development and supervision has been recognized internationally. It helps further promote the development of “first-tier approval” capabilities and mechanisms for innovative drugs, and is deeply involved in formulating international rules for drug development and registration, and accelerating the construction of an international medical innovation hub.

ICH became the 20th member of its supervisory authority through Hong Kong, China (represented by the Hong Kong Pharmacy and Poison Administration) at a conference held in the Czech Republic on November 17, 2026. Other ICH regulators include China's National Drug Administration, as well as regulators in Europe, Switzerland, the United Kingdom, and the US.

The Secretary for Health and Services of Hong Kong, Professor Lo Chung-mau, said, “The HKSAR Government sincerely thanks the country for continuing to fully support Hong Kong's development as an international healthcare innovation hub. Hong Kong, China became a member of the ICH Supervisory Authority, fully demonstrating the unique advantages of 'one country, two systems'. Since Hong Kong became an ICH observer on October 31, 2023, it has made every effort to meet the ICH requirements with strong support from the country before it can officially become a member of the ICH Supervisory Authority within just 3 years. Compared with the 8 to 10 years previously estimated by the government based on international experience, the process has been greatly accelerated.”

Professor Lo Chung-mau added, “Looking forward to the future, the HKSAR Government will actively cooperate with the national “15th Five-Year Plan” in accordance with the “Hong Kong Special Administrative Region's First Five-Year Plan for Economic and Social Development (2026-2030)” to support biomedical clinical research and development and optimize the review and approval of innovative drugs and clinically urgently needed drugs. The HKSAR Government will establish the Drug and Medical Device Supervision and Administration Center (DRC) next month to establish independent drug review and approval capabilities, actively participate in international cooperation, build Hong Kong into an international medical innovation hub, and better integrate and serve the overall development of the country.”

Dr Lam Man-kin, Director of Health of Hong Kong, said, “Joining ICH is an important milestone in drug review, approval and regulatory reform in Hong Kong, and is particularly important for the upcoming Pharmaceutical Device Supervision Centre. The Pharmaceutical Device Regulatory Center will establish a professional team for independent review and approval in accordance with ICH technical requirements, improve the efficiency of the evaluation of innovative drugs, and dispatch experts to participate in formulating and revising ICH guidelines to contribute to the scientific standardization of global drug regulation. Hong Kong is now also a member of the ICH Supervisory Authority and a member of the 'Drug Inspection Cooperation Program' (PIC/S). The Drug Control Centre will strive to become an authoritative international supervisory authority based on science.”

ICH is an international pharmaceutical coordination authority. Its purpose is to coordinate technical requirements for global drug registration, formulate guidelines for the highest international standards relating to safety, efficacy and quality, and protect public health. Meanwhile, PIC/S is an authoritative international organization composed of drug regulatory agencies from many countries and regions. Its mission is to lead the development of international pharmaceuticals, formulate and implement strict “production quality management standards” guidelines and quality management systems for drug inspection. Hong Kong, China passed the audit in 2015 and officially became a PIC/S member on January 1, 2016.